Project Grant HT94252410528
Award Date
6/1/24
Completion Date
5/31/28
Dollars Obligated
$1.1M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Tacoma, WA 98402, USA
Similar Awards
The Geneva Foundation will receive $910,559 under a Cooperative Agreement awarded by the Department of the Army Medical Command on August 15, 2022. The funding supports a research project titled "In Vivo Imaging of Lymphatic Circulation: Measurement of Brain Interstitial Fluid Flow During Wake and Sleep with Ultra-High Performance MRI." The project aims to investigate medical solutions for the battlefield by transforming health care through innovative and impactful research, as part of...
This Cooperative Agreement award in the amount of $744,897.00 was provided by the Uniformed Services University of the Health Sciences under the Uniformed Services University Medical Research Projects program (CFDA 12.750). The award supports medical research, development, and clinical trials conducted by The Geneva Foundation, a 501(c)(3) non-profit organization based in Tacoma, Washington. The research will focus on advancing military medical capabilities and addressing critical healthcare...
The U.S. Defense Health Agency awarded a $325,650 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to The Geneva Foundation, a Tacoma, WA-based non-profit organization, to conduct an "Assessment of Changes in Human Blood Proteome Following Total Sleep Deprivation." The research project, with a performance period from March 1, 2025 to February 28, 2027, will investigate innovative approaches to understanding the impact of sleep deprivation on the...
The Geneva Foundation was awarded a $1,597,740 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from June 2022 to June 2026 to develop new methods for accessing extracellular vesicle MDM2 DNA cargo as a potential liposarcoma biomarker. Through support of basic, applied, and advanced biomedical research, the Military Medical Research and Development program aims to transform...
The Department of the Army Medical Command awarded The Geneva Foundation a $6,663,794 Project Grant under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant, awarded on September 30, 2024, will fund the "PRECISIE RTD TRIAL: PRECISION WITH RETURN-TO-DUTY DECISIONS IN THE MILITARY" research initiative. This project aims to transform healthcare for military service members by investigating innovative approaches to disease prevention, diagnosis,...
The Geneva Foundation was awarded a $1,054,546 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The three-year grant will support research into the role of U2AF1 mutations in myelodysplastic syndrome and their potential role as a noncanonical splicing factor in bone marrow failure. Through July 2025, the Geneva Foundation will investigate how these genetic mutations impact splicing and the development of...
This Project Grant award for $366,000.00, awarded on Sep 30, 2024 by the Defense Health Agency, supports research conducted by The Geneva Foundation to identify functional structural variants that influence therapy outcomes for human castration-resistant prostate cancer. The award is funded through the Military Medical Research and Development program (CFDA 12.420), which supports a broad range of biomedical research initiatives to improve health outcomes for military service members,...
The Geneva Foundation received a $4,676,544 Project Grant award from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420) to develop and validate innate immunome-targeted therapies to create a pro-survival and organ-protective phenotype after hemorrhage at the point of injury. Specifically, the Foundation will investigate immunotherapy approaches for hemorrhage treatments using innate immunome-targeted therapies from July 1, 2023 to...
The U.S. Department of Defense's Defense Health Agency awarded a $488,000 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to The Geneva Foundation, a non-profit organization. The grant, awarded on July 1, 2024, supports research to investigate novel mechanisms of regulating the PAX3-FOXO1 fusion oncogene in rhabdomyosarcoma, a type of soft tissue cancer. The research aims to advance treatments for this rare and aggressive form of cancer, with a projected...
The Geneva Foundation was awarded a $362,100 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program to conduct research toward the dual targeting of HER2 and androgen receptor in patients with high-risk, hormone-naive prostate cancer with curative intent. The two-year grant project period runs from June 1, 2022 to May 31, 2024. Through this funding, The Geneva Foundation will perform applied medical research investigating...